Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPA5 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Tennessee
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
LPA5 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the lysophosphatidic acid receptor 5 (LPA5), a G protein-coupled receptor (GPCR). Research presented by the University of Tennessee and Lexicon Pharmaceuticals indicates that LPA5 plays a complex role in melanoma progression. In B16 melanoma cell lines, siRNA-mediated knockdown of LPA5 was found to increase in vitro invasion, suggesting that the receptor may normally inhibit certain invasive pathways in these specific cells. Conversely, in vivo studies using LPA5 knockout mice showed a significant reduction in lung metastasis, suggesting that LPA5 signaling in the tumor microenvironment or stromal tissues is a potential target for preventing cancer spread.
- Other names
- LPAR5 siRNALPAR-5 siRNALPAR 5 siRNAlysophosphatidic acid receptor 5 siRNA
02
Targets
AGO2 (Argonaute RISC catalytic component 2)LPAR5 (Lysophosphatidic acid receptor 5)
Beyond the preview
Go deeper on LPA5 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPA5 siRNA.